Cardiomyocytes derived from human induced pluripotent stem cells (iPSC) are a reliable and critical in vitro cellular model for drug-induced cardiotoxicity and drug discovery. To complement our gold standard iCell® Cardiomyocytes2, 01434, we developed iCell Cardiomyocytes2, 11713 from an alternative donor iPSC (termed 11713). This iPSC line was generated from blood cells donated by an apparently healthy normal female donor (age range 35-39) using episomal vectors for footprint-free reprogramming. These 11713 iPSCs differentiate into a highly pure population of cardiomyocytes (>95% cTNT positive cells) that beat spontaneously with consistent beat rate (34±6 bpm) and field potential duration (394±31 msec) across batches at day 7 post thaw. Finally, iCell Cardiomyocytes2, 11713 were challenged with CiPA-28 compounds (Comprehensive in Vitro Proarrhythmia Assay, CiPA) and the field potential duration and action potential morphology responses were measured following our newly developed application protocol titled “Using LEAP to Measure Cardiac Action Potential Morphology”.

These data show that iCell Cardiomyocytes2, 01434, and now iCell Cardiomyocytes2, 11713, are reliable models to study drug-induced cardiotoxicity, in particular proarrhythmia.

During this webinar, you will learn about:

  • Our expansion of the enhanced iCell Cardiomyocytes2 product line to provide more donor background options.
  • iCell Cardiomyocytes2, 11713 electrophysiological responses to CiPA-28 reference compounds.
  • The development of a new application protocol that not only enables quantitation of compound effects on action potential morphology, but also offers automated detection and classification of arrhythmias.

Please complete the form below to view this webinar: